Jianming Lu

2.2k total citations · 1 hit paper
27 papers, 1.6k citations indexed

About

Jianming Lu is a scholar working on Molecular Biology, Oncology and Infectious Diseases. According to data from OpenAlex, Jianming Lu has authored 27 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 10 papers in Oncology and 3 papers in Infectious Diseases. Recurrent topics in Jianming Lu's work include Angiogenesis and VEGF in Cancer (5 papers), Chemokine receptors and signaling (4 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). Jianming Lu is often cited by papers focused on Angiogenesis and VEGF in Cancer (5 papers), Chemokine receptors and signaling (4 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). Jianming Lu collaborates with scholars based in United States, Japan and China. Jianming Lu's co-authors include Eric Delpire, Kerstin Piechotta, Roger England, Tina Thorne, Eileen L. Heinrich, Joseph Kim, Keqiang Zhang, Wendy Lee, Wei Wen and Jun Zhang and has published in prestigious journals such as Science, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Jianming Lu

26 papers receiving 1.6k citations

Hit Papers

Structural impact on SARS-CoV-2 spike protein by D614G su... 2021 2026 2022 2024 2021 50 100 150 200 250

Peers

Jianming Lu
Alessandro Sardini United Kingdom
Marian B. Meyers United States
Craig W. Vander Kooi United States
Pamela Mertz United States
Diego Acosta‐Alvear United States
Assia Shisheva United States
Brian A. Perrino United States
Alessandro Sardini United Kingdom
Jianming Lu
Citations per year, relative to Jianming Lu Jianming Lu (= 1×) peers Alessandro Sardini

Countries citing papers authored by Jianming Lu

Since Specialization
Citations

This map shows the geographic impact of Jianming Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianming Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianming Lu more than expected).

Fields of papers citing papers by Jianming Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianming Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianming Lu. The network helps show where Jianming Lu may publish in the future.

Co-authorship network of co-authors of Jianming Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Jianming Lu. A scholar is included among the top collaborators of Jianming Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianming Lu. Jianming Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shi, Wei, Hanqin Peng, Sophia Rits‐Volloch, et al.. (2025). Effect of the S2’ site cleavage on SARS-CoV-2 spike. Nature Communications. 16(1). 11675–11675.
2.
Yavuz, Betül Gök, Yehia I. Mohamed, Abdullah Esmail, et al.. (2024). Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection. Frontiers in Pharmacology. 15. 1291212–1291212. 3 indexed citations
3.
Petersen, Jennifer D., Jianming Lu, Wendy Fitzgerald, et al.. (2022). Unique Aggregation of Retroviral Particles Pseudotyped with the Delta Variant SARS-CoV-2 Spike Protein. Viruses. 14(5). 1024–1024. 4 indexed citations
4.
Zhang, Jun, Yongfei Cai, Tianshu Xiao, et al.. (2021). Structural impact on SARS-CoV-2 spike protein by D614G substitution. Science. 372(6541). 525–530. 270 indexed citations breakdown →
5.
Zhang, Zhifang, Annie Yang, Shyambabu Chaurasiya, et al.. (2021). CF33-hNIS-antiPDL1 virus primes pancreatic ductal adenocarcinoma for enhanced anti-PD-L1 therapy. Cancer Gene Therapy. 29(6). 722–733. 11 indexed citations
6.
Lee, Sangjun, Eileen L. Heinrich, Lily Li, et al.. (2015). CCR9‐mediated signaling through β‐catenin and identification of a novel CCR9 antagonist. Molecular Oncology. 9(8). 1599–1611. 23 indexed citations
7.
Lee, Sangjun, Eileen L. Heinrich, Jianming Lu, et al.. (2015). Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. Pancreas. 45(2). 286–292. 15 indexed citations
8.
Choi, Audrey H., Jianming Lu, Sang Jun Lee, et al.. (2015). Abstract 780: Multi-targeted tyrosine kinase inhibitor Cabozantinib as a therapeutic agent in MET-overexpressing gastric cancer. Cancer Research. 75(15_Supplement). 780–780. 1 indexed citations
9.
Heinrich, Eileen L., Amanda K. Arrington, Carrie Luu, et al.. (2013). Paracrine Activation of Chemokine Receptor CCR9 Enhances The Invasiveness of Pancreatic Cancer Cells. Cancer Microenvironment. 6(3). 241–245. 25 indexed citations
10.
Heinrich, Eileen L., Wendy Lee, Jianming Lu, Andrew M. Lowy, & Joseph Kim. (2012). Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. Journal of Translational Medicine. 10(1). 68–68. 100 indexed citations
11.
Wang, Xiao, Xiaolei Wang, Xianghui Tan, et al.. (2012). A Biomimetic Route for Construction of the [4+2] and [3+2] Core Skeletons of Dimeric Pyrrole–Imidazole Alkaloids and Asymmetric Synthesis of Ageliferins. Journal of the American Chemical Society. 134(45). 18834–18842. 39 indexed citations
12.
Kim, Joseph, M.L. Richard Yip, Xiaoming Shen, et al.. (2012). Identification of Anti-Malarial Compounds as Novel Antagonists to Chemokine Receptor CXCR4 in Pancreatic Cancer Cells. PLoS ONE. 7(2). e31004–e31004. 57 indexed citations
13.
Liang, Wei, Maciej Kujawski, Jun Wu, et al.. (2010). Antitumor Activity of Targeting Src Kinases in Endothelial and Myeloid Cell Compartments of the Tumor Microenvironment. Clinical Cancer Research. 16(3). 924–935. 51 indexed citations
14.
Zhang, Keqiang, Shuya Hu, Jun Wu, et al.. (2009). Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Molecular Cancer. 8(1). 11–11. 90 indexed citations
15.
Liang, Wei, Andreas Herrmann, Michael Hedvat, et al.. (2008). The Src family kinase inhibitor, dasatinib, inhibits angiogenesis in vitro and in vivo. Cancer Research. 68. 270–270. 3 indexed citations
16.
Piechotta, Kerstin, Jianming Lu, & Eric Delpire. (2002). Cation Chloride Cotransporters Interact with the Stress-related Kinases Ste20-related Proline-Alanine-rich Kinase (SPAK) and Oxidative Stress Response 1 (OSR1). Journal of Biological Chemistry. 277(52). 50812–50819. 314 indexed citations
17.
Zhang, Shimin, et al.. (2001). A SIMPLIFIED METHOD FOR LARGE SCALE QUANTIFICATION OF TRANSCRIPTIONAL ACTIVITY AND ITS USE IN STUDIES OF STEROIDS AND STEROID RECEPTORS. Journal of Receptors and Signal Transduction. 21(1). 71–84. 2 indexed citations
18.
Delpire, Eric, et al.. (1999). Deafness and imbalance associated with inactivation of the secretory Na-K-2Cl co-transporter. Nature Genetics. 22(2). 192–195. 328 indexed citations
19.
Huang, Hai, et al.. (1998). Synthesis Of A New Series Of Cyclic Pseudopeptides Containing Pyridine As Backbone Modifier. Synthetic Communications. 28(24). 4639–4647. 7 indexed citations
20.
Chen, Fei, et al.. (1992). A sensitive fluorometric assay for reducing sugars. Life Sciences. 50(9). 651–659. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026